Logo image of CCCC

C4 THERAPEUTICS INC (CCCC) Stock Fundamental Analysis

NASDAQ:CCCC - Nasdaq - US12529R1077 - Common Stock - Currency: USD

3.01  +0.02 (+0.67%)

After market: 3.01 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CCCC. CCCC was compared to 572 industry peers in the Biotechnology industry. While CCCC has a great health rating, there are worries on its profitability. CCCC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CCCC has reported negative net income.
CCCC had a negative operating cash flow in the past year.
In the past 5 years CCCC always reported negative net income.
CCCC had negative operating cash flow in 4 of the past 5 years.
CCCC Yearly Net Income VS EBIT VS OCF VS FCFCCCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 50M -50M -100M

1.2 Ratios

CCCC has a better Return On Assets (-28.05%) than 70.69% of its industry peers.
The Return On Equity of CCCC (-43.48%) is better than 69.45% of its industry peers.
Industry RankSector Rank
ROA -28.05%
ROE -43.48%
ROIC N/A
ROA(3y)-27.17%
ROA(5y)-26.81%
ROE(3y)-39.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CCCC Yearly ROA, ROE, ROICCCCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

1.3 Margins

CCCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CCCC Yearly Profit, Operating, Gross MarginsCCCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

CCCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CCCC has more shares outstanding
CCCC has more shares outstanding than it did 5 years ago.
CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CCCC Yearly Shares OutstandingCCCC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M
CCCC Yearly Total Debt VS Total AssetsCCCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

CCCC has an Altman-Z score of -1.48. This is a bad value and indicates that CCCC is not financially healthy and even has some risk of bankruptcy.
CCCC has a Altman-Z score (-1.48) which is in line with its industry peers.
There is no outstanding debt for CCCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.48
ROIC/WACCN/A
WACC9.65%
CCCC Yearly LT Debt VS Equity VS FCFCCCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 6.31 indicates that CCCC has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.31, CCCC is doing good in the industry, outperforming 63.23% of the companies in the same industry.
A Quick Ratio of 6.31 indicates that CCCC has no problem at all paying its short term obligations.
CCCC has a better Quick ratio (6.31) than 63.59% of its industry peers.
Industry RankSector Rank
Current Ratio 6.31
Quick Ratio 6.31
CCCC Yearly Current Assets VS Current LiabilitesCCCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.00% over the past year.
Looking at the last year, CCCC shows a very strong growth in Revenue. The Revenue has grown by 65.51%.
CCCC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.40% yearly.
EPS 1Y (TTM)37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
Revenue 1Y (TTM)65.51%
Revenue growth 3Y-14.49%
Revenue growth 5Y1.4%
Sales Q2Q%38.75%

3.2 Future

The Earnings Per Share is expected to grow by 18.72% on average over the next years. This is quite good.
The Revenue is expected to grow by 46.91% on average over the next years. This is a very strong growth
EPS Next Y40.95%
EPS Next 2Y13.64%
EPS Next 3Y9.6%
EPS Next 5Y18.72%
Revenue Next Year66.27%
Revenue Next 2Y-9.33%
Revenue Next 3Y-4.62%
Revenue Next 5Y46.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CCCC Yearly Revenue VS EstimatesCCCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
CCCC Yearly EPS VS EstimatesCCCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20 30 40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CCCC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCCC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CCCC Price Earnings VS Forward Price EarningsCCCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CCCC Per share dataCCCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.64%
EPS Next 3Y9.6%

More info and screens

0

5. Dividend

5.1 Amount

CCCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

C4 THERAPEUTICS INC

NASDAQ:CCCC (2/21/2025, 8:05:56 PM)

After market: 3.01 0 (0%)

3.01

+0.02 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-06 2025-05-06
Inst Owners85.76%
Inst Owner Change-79.13%
Ins Owners2.59%
Ins Owner Change31.55%
Market Cap212.48M
Analysts80
Price Target16.32 (442.19%)
Short Float %12.75%
Short Ratio3.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.56%
Min EPS beat(2)9.7%
Max EPS beat(2)31.42%
EPS beat(4)2
Avg EPS beat(4)6.55%
Min EPS beat(4)-14.38%
Max EPS beat(4)31.42%
EPS beat(8)4
Avg EPS beat(8)6.26%
EPS beat(12)7
Avg EPS beat(12)9.45%
EPS beat(16)11
Avg EPS beat(16)16.28%
Revenue beat(2)2
Avg Revenue beat(2)186.74%
Min Revenue beat(2)146.07%
Max Revenue beat(2)227.41%
Revenue beat(4)3
Avg Revenue beat(4)77.63%
Min Revenue beat(4)-63.22%
Max Revenue beat(4)227.41%
Revenue beat(8)4
Avg Revenue beat(8)31.64%
Revenue beat(12)6
Avg Revenue beat(12)39.55%
Revenue beat(16)10
Avg Revenue beat(16)39.58%
PT rev (1m)-0.89%
PT rev (3m)-0.89%
EPS NQ rev (1m)-1.94%
EPS NQ rev (3m)-1.94%
EPS NY rev (1m)-1.41%
EPS NY rev (3m)-1.87%
Revenue NQ rev (1m)-3.57%
Revenue NQ rev (3m)-3.57%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.31
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)-1.01
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS0.48
BVpS3.44
TBVpS3.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.05%
ROE -43.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.17%
ROA(5y)-26.81%
ROE(3y)-39.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.29%
Cap/Sales 1.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.31
Quick Ratio 6.31
Altman-Z -1.48
F-Score5
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)168.05%
Cap/Depr(5y)125.73%
Cap/Sales(3y)9.57%
Cap/Sales(5y)7.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
EPS Next Y40.95%
EPS Next 2Y13.64%
EPS Next 3Y9.6%
EPS Next 5Y18.72%
Revenue 1Y (TTM)65.51%
Revenue growth 3Y-14.49%
Revenue growth 5Y1.4%
Sales Q2Q%38.75%
Revenue Next Year66.27%
Revenue Next 2Y-9.33%
Revenue Next 3Y-4.62%
Revenue Next 5Y46.91%
EBIT growth 1Y16.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.1%
EBIT Next 3Y-6.33%
EBIT Next 5YN/A
FCF growth 1Y32.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.5%
OCF growth 3YN/A
OCF growth 5YN/A